Mibenratide
Alternative Names: COR-1; JNJ-54452840Latest Information Update: 02 Oct 2021
At a glance
- Originator Corimmun
- Developer Corimmun; Janssen-Cilag
- Class Cyclic peptides; Disulfides; Heart failure therapies; Peptides
- Mechanism of Action Beta 1 adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 18 Sep 2015 No recent reports on development identified - Phase-I for Heart failure (In volunteers) in USA (IV)
- 18 Sep 2015 No recent reports on development identified - Phase-II for Heart failure in Germany (IV)
- 31 Aug 2013 Corimmun completes a phase II trial in Heart failure in Germany (NCT01391507)